Início › Mielofibrose › Texas
Ensaios clínicos de Mielofibrose em Texas
20 estudos para Mielofibrose estão buscando participantes em locais em Texas.
Cidades em Texas
Texto oficial do estudo (Inglês)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- MD Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Texas Oncology PA Dallas Presbyterian Hospital, Dallas
- MD Anderson Cancer Center, Houston
- SCRI Texas Oncology Northeast Texas, Tyler
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07357727A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- The University of Texas, MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Baylor University Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- e mais 1
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07623161Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- MD Anderson, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT06343805High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- MD Anderson Cancer Center, Houston
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06345495A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood, Dallas
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Texas M. D. Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT07441694Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de jul. de 2026 · NCT07128381Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
- MD Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 26 de mai. de 2026 · NCT06327100Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 13 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04771572Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 20 de abr. de 2026 · NCT06517875A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Md Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 17 de abr. de 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
RecrutandoFase 2
Idades de 18 a 66 · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06859424A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- MD Anderson, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 12 de fev. de 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UT - SouthWestern, Dallas
- U.T. MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at San Antonio, San Antonio
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2025 · NCT06479135Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- The University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de abr. de 2025 · NCT05423691Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- The University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 21 de fev. de 2023 · NCT05280509Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.